In one paragraphArticle in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
8 authors.
Hsin Chieh WuCollège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0000-0001-8793-7821 Emmanuel LaplantineCollège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0000-0002-5916-4654 Cécile EsnaultCollège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0000-0001-9883-2443 Michiko Niwa-KawakitaCollège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0000-0002-9450-583X Yi ZhangCollège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0009-0002-0919-9813 Viviane De Almeida BastosSorbonne Université, UMS 37 PASS, P3S, Institut National de la Santé et de la Recherche Médicale , Paris, France.ORCID 0000-0001-5543-4058 Marie-Claude Geoffroy *Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0000-0001-8298-467X Hugues de Thé *Collège de France, Oncologie Cellulaire et Moléculaire, PSL University, CIRB, Institut National de la Santé et de la Recherche Médicale UMR 1050, Centre National de la Recherche Scientifique UMR 7241 , Equipe Labellisée par la Ligue contre le Cancer, Paris, France.ORCID 0000-0002-1113-4472 Funding
European Research Council PML-Therapy #785917European Research Council RARA-AML #101140666French National Research Agency ANR-23-IAHU-0005Institut National du Cancer PLBIO #2022-105Paris St. Louis Leukemia Institute
6 · The paper itselfAbstract
While acute promyelocytic leukemia (APL) is always driven by fusions involving one of the three retinoic acid receptors, why PML and RARA are the preferred fusion partners has remained largely unsettled. Here, we demonstrate that corepressor (NCoR) binding onto the RARA moiety of PML::RARA is required for hematopoietic progenitor immortalization. We establish that PML-mediated tethering of the UBC9 SUMO-conjugating enzyme onto PML::RARA enforces SUMO2 conjugation of multiple RARA partner proteins, notably the NCoR complex, boosting its repressive power. PML mutants that fail to recruit UBC9 yield PML::RARA fusions that promote neither NCoR sumoylation nor transformation. Conversely, direct UBC9/RARA fusion drives both efficient corepressor complex sumoylation and immortalization. Sumoylation inhibitors reactivate retinoic acid target genes in PML::RARA-expressing, but not in RARA-expressing, progenitors and trigger APL differentiation. Thus, fusion of PML to RARA entails an unexpected gain of function that boosts RARA-mediated transcriptional repression through sumoylation of PML::RARA-bound proteins, explaining the recurrent implication of PML and RARA in APL pathogenesis.
Indexed as
Hematopoietic Stem CellsLeukemia, Promyelocytic, AcuteNuclear ProteinsOncogene Proteins, FusionPromyelocytic Leukemia ProteinReceptors, Retinoic AcidRetinoic Acid Receptor alphaSumoylationAnimalsHumansMiceNuclear Receptor Co-Repressor 1Transcription FactorsTretinoinUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9Nuclear ProteinsNuclear Receptor Co-Repressor 1Oncogene Proteins, FusionPML protein, humanPml protein, mousePromyelocytic Leukemia Proteinpromyelocytic leukemia-retinoic acid receptor alpha fusion oncoproteinRARA protein, humanReceptors, Retinoic AcidRetinoic Acid Receptor alphaTranscription FactorsTretinoinUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9
Identifiers
PMID42663568
PMCPMC13523716
What Socratic holds
Textmetadata
Read underepoch 390